Priya Umapathi, MD speaks with six HFSA past presidents live from ASM 2025. Nancy M. Albert, PhD, CCNS, CCRN, NE-BC, Biykem Bozkurt, MD, PhD, Jim Fang, MD, FHFSA, Mark H. Drazner, MD MSc, Michael Felker, MD, FHFSA, and Ken Margulies, MD, FHFSA discuss their journeys, achievements, and the future of heart failure — from prevention to precision medicine and AI. 

Guest editors Drs. Mak, Burkhoff, and Belkin join Heart Failure Beat to unpack the Journal of Cardiac Failure Hemodynamics Focus Issue. They discuss how renewed attention to pressure-volume loops, ECMO, and patient perspectives is reviving interest in hemodynamics as a vital foundation for heart failure care. Discover how simple physiological insights continue to drive complex innovations—and why now is the time to bring hemodynamics back to the center of cardiovascular practice. https://onlinejcf.com/current

Meet the editorial team behind JCF-Intersections, HFSA’s and the JCF Family of Journal’s new open-access journal. Drs. Jason Katz and Nosheen Reza share their vision for a journal that sits at the crossroads of heart failure and innovation. From unique article types to early-career mentorship, this is a must-listen for anyone in cardiovascular care. Listen now and read the debut issue of JCF-Intersections, out now at onlinejcfi.org. 

In this episode of the Heart Failure Beat, Dr. Eric Adler of UC San Diego Health joins the show to discuss his landmark gene therapy trial for Danon disease, recently published in the New England Journal of Medicine. Dr. Adler recounts the powerful bedside-to-bench-to-bedside story that led to the development of a groundbreaking treatment for this severe, genetic cardiomyopathy. He explains the mechanics and evolution of gene therapy, its promise in treating monogenic heart failure syndromes, and the early but encouraging clinical outcomes—like dramatic reductions in troponins and heart mass. The episode also explores regulatory and safety challenges, delivery limitations, and the critical role of patient advocacy. Whether you’re a heart failure specialist or a translational researcher, this conversation offers compelling insights into the future of precision therapies in cardiology.

In this episode of Heart Failure Beat, Dr. Shashank Sinha—Medical Director of the CICU at Inova Fairfax—joins hosts Dr. Priya Umapathi and Dr. Michael Beasley to unpack the 2025 ACC Expert Consensus Statement on Cardiogenic Shock. Together, they explore the updated SHARC classification, staging systems, and the S.U.S.P.E.C.T. mnemonic for early recognition. Dr. Sinha shares practical insights on invasive hemodynamics, shock team composition, and new data on mechanical circulatory support. Plus, hear his “Top 10 Takeaways” for managing this complex and dynamic condition. Whether you work in a tertiary center or a community hospital, this episode delivers guidance for real-world care.

In this compelling episode of the HF Beat, join hosts Michael Beasley, MD and Priya Umapathi, MD and an esteemed panel of experts, including Dr. Eileen Hsich, Dr. Anu Lala, and Dr. Ilan Goldenberg, as they delve into the nuanced world of sex differences in heart failure. This conversation spans three key topics: identifying traditional and sex-specific risk factors for heart failure, addressing disparities in diagnosis and treatment, and exploring the implications of these differences on therapeutic responses and device-based interventions. Highlights include discussions on under diagnosis in women due to natriuretic peptide thresholds, CRT’s heightened benefits in women with non-ischemic cardiomyopathy, and the urgent need for inclusive clinical trials. With actionable insights and cutting-edge research, this episode equips heart failure clinicians with essential knowledge to better serve our heart failure patient population. Tune in to explore how advancing sex-specific research can transform heart failure care for all.

In this episode of the HF Beat, our hosts Michael and Priya sit down with Dr. Biykem Bozkurt, a leading expert in heart failure, to discuss the alarming rise of heart failure mortality rates in not just older patients but especially in our younger patients and certain minority groups. Dr. Bozkurt delves into the 2024 HF Stats report, highlighting concerning trends such as increasing incidence and prevalence, widening disparities in care, lack of available care, and the continued underutilization of guideline-directed therapies. We explore the root causes of these troubling statistics, including social determinants of health, access to care, and the impact of risk factors like obesity and diabetes. Dr. Bozkurt emphasizes the critical need for early recognition and treatment of risk factors to prevent heart failure progression and improve outcomes for all patients.

On this episode of HF Beat, Michael Felker, MD, FHFSA, current HFSA President, shares HFSA’s vision for the coming year, highlighting initiatives to expand patient and caregiver engagement, bolster research funding through the Heart Failure Research Foundation, and inspire the next generation of heart failure specialists.

This episode highlights critical updates in heart failure care with insights from leading experts. First, Marat Fudim, MD, MHS discusses the HFSA statement on device-based therapies, including emerging innovations like cardiac contractility modulation and remote monitoring tools. Next, Michelle Weisfelner Bloom, MD and Ana Barac, MD, PhD present the groundbreaking cardio-oncology and heart failure scientific statement, emphasizing the integration of cancer therapies and heart care. They explore strategies to manage treatment-related cardiac dysfunction and propose a "permissive toxicity" framework. Finally, Sarah Chuzi, MD, MSc and Haider Warraich, MD detail HFSA's palliative care consensus, providing actionable guidance for integrating primary and specialty palliative care in heart failure management. This episode equips clinicians with practical strategies and a forward-looking perspective to enhance patient outcomes.

In this episode of the Heart Failure Beat, our hosts sit down with Dr. James Fang, immediate past president of the Heart Failure Society of America, to discuss highlights from his term and the advancements shaping heart failure care. Dr. Fang reflects on major scientific breakthroughs, including the SEQUOIA-HCM and FINEARTS-HF trials, and the role of GLP-1 agonists. He also emphasizes the societal importance of accessible treatments, especially with recent legislative changes impacting drug affordability. Dr. Fang highlights initiatives like the Heart Failure Research Foundation’s support for early-career investigators and the Journal of Cardiac Failure's expansion into Open Access, which together aim to foster collaboration and drive innovation. Tune in for insights on pivotal developments, the future of heart failure as a specialty, and the Society’s commitment to fostering a multidisciplinary approach to patient care.